MD Anderson's fifth annual Boot Walk to End Cancer® goes virtual Nov. 7
HOUSTON ― The University of Texas MD Anderson Cancer Center will host the fifth annual Boot Walk to End Cancer® virtually on Saturday, Nov. 7. The virtual walk will take place online and in neighborhoods across the country in an effort to keep participants, their families and their communities safe and as part of MD Anderson's commitment to prioritizing the health and safety of patients, workforce members and the greater Houston community...
MD Anderson, UT Austin Announce First Collaborative Projects in United Fight to End Cancer
Cancer remains one of the leading causes of death worldwide. While advances in cancer diagnoses and treatments are promising, more is needed...
MD Anderson and Allogene Therapeutics announce strategic collaboration to accelerate advancement of allogeneic CAR T therapy (AlloCAR T)
The University of Texas MD Anderson Cancer Center and Allogene Therapeutics, Inc. today announced a strategic five-year collaboration agreement...
Dual checkpoint blockade promising as pre-surgical approach for certain patients with localized bladder cancer
Neoadjuvant, or pre-surgical, combination treatment with the immune checkpoint inhibitors tremelimumab (anti-CTLA-4) and durvalumab (anti-PD-1) was well-tolerated and showed early signs of activity in certain patients with localized bladder cancer who do not have standard treatment options available, according to a Phase I clinical trial conducted by The University of Texas MD Anderson Cancer Center.
This represents the first...
Study finds cancer mutations accumulate in distinct regions based on structure of genome and mutational causes
A new study from researchers at The University of Texas MD Anderson Cancer Center has discovered that mutations found in cancers do not accumulate...
Next-gen bioinformatics tool enables big data analysis without programming expertise
A new data analysis tool developed by researchers at The University of Texas MD Anderson Cancer Center incorporates a user-friendly,...
MD Anderson and Taiho Pharmaceutical announce collaboration to accelerate development of novel therapies for brain metastasis and other unmet medical needs
The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic collaboration...
Monica Johnson receives Julie and Ben Rogers Award for Excellence
The University of Texas MD Anderson Cancer Center has awarded Monica Johnson, M.H.A., C.P.X.P., the Julie and Ben Rogers Award for Excellence...
KRAS inhibitor sotorasib appears safe, achieves durable clinical benefit in early trial
ABSTRACT: 1257O
In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor...
MD Anderson and Xencor enter strategic collaboration to advance investigational XmAb® drug candidates
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic collaboration to study investigational...
Lung cancer trial of RET inhibitor selpercatinib achieves durable responses in majority of patients with RET gene fusions
For patients with non-small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and...
Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations
In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor...
Study shows frequently used serology test may not detect antibodies that could confirm protection against reinfection of COVID-19
Two different types of detectable antibody responses in SARS-CoV-2 (COVID-19) tell very different stories and may indicate ways to enhance...
Cancer care and screenings must remain a priority during COVID-19
The University of Texas MD Anderson Cancer Center is committed to safely providing patient care and cancer screenings throughout the novel...
Implementation of social distancing policies correlates with significant reduction in SARS-CoV-2 transmission
According to researchers from The University of Texas MD Anderson Cancer Center, the implementation of social distancing policies corresponded...
MD Anderson honored to rank as nation’s best hospital for cancer care
The University of Texas MD Anderson Cancer Center is honored to rank No. 1 in cancer care in the U.S. News & World Report’s 2020...
MD Anderson and Sanofi announce strategic collaboration to accelerate oncology research and development
The University of Texas MD Anderson Cancer Center and Sanofi today announced a five-year strategic collaboration to accelerate the development...
MD Anderson and UT Austin Create Unique Data-Driven Collaboration to Eliminate Cancer Using Novel Mathematical and Computational Approaches
The University of Texas MD Anderson Cancer Center and two institutions at The University of Texas at Austin – the Oden Institute for Computational...
Study shows sedentary behavior independently predicts cancer mortality
In the first study to look at objective measures of sedentary behavior and cancer mortality, researchers from The University of Texas MD Anderson...
Combination biomarker predicts response to immune checkpoint therapy in patients with advanced bladder cancer
In patients with metastatic bladder cancer, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical...
MD Anderson and Philips collaborate to facilitate personalized oncology treatments and clinical trial matching based on genomic markers
The University of Texas MD Anderson Cancer Center and Royal Philips today announced a collaboration to provide oncologists with evidence-based...
MD Anderson and Rakuten Medical announce strategic alliance to advance Illuminox platform for cancer treatments
The University of Texas MD Anderson Cancer Center and Rakuten Medical, Inc. today announced a strategic alliance collaboration agreement to...
Statement from Peter WT Pisters, M.D., regarding the tragic death of George Floyd
At MD Anderson, we are filled with anguish and deep sorrow over the senseless acts of racism and violence in our country and the tragic death...
Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors
ABSTRACT: #102
The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4...
Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions
ABSTRACT: #109
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety...
Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response
Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate...
Novel targeted drug induced positive response for patients with von Hippel-Lindau disease–associated kidney cancer
ABSTRACT: #5003
In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with...
MD Anderson and Innovent Biologics announce a strategic collaboration to develop anti-PD-1 therapy TYVYT® (sintilimab injection) in rare cancers
The University of Texas MD Anderson Cancer Center and Innovent Biologics, Inc. today announced a strategic collaboration agreement to co-develop...
MD Anderson, Ipsen advance new therapy with potential benefit for underserved lung and ovarian cancer patients
ABSTRACT: DDT01-03
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers...
Majority of patients responded in CAR T-cell trial for mantle cell lymphoma
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma...
Immunotherapy effective in metastatic prostate cancers with specific markers of immune activation
Although metastatic castration-resistant prostate cancer (mCRPC) typically has limited response to immunotherapy, a subset of patients with...
New therapeutic strategies proposed for some lung and kidney cancers
New findings from researchers at The University of Texas MD Anderson Cancer Center about how some cancer cells become “addicted” to glucose...
Combination creates powerful central memory T cells for cellular therapy
Treating T cells harvested from a patient with a combination of an epigenetic drug and a cytokine while expanding the cells in the lab re-programs...
Study sheds light on fatty acid’s role in “chemobrain” and multiple sclerosis
Medical experts have always known myelin, the protective coating of nerve cells, to be metabolically inert. A study led by The University...
Pembrolizumab shows promise for some advanced, hard-to-treat rare cancers
A study conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated acceptable toxicity and anti-tumor activity...
Osteosarcoma profiling reveals why immunotherapy remains ineffective
Comprehensive profiling of tumor samples taken from patients with osteosarcoma shows that multiple factors contribute to the traditionally...
MD Anderson announces strategic collaboration with Denali Therapeutics to research and develop targeted therapies for neurodegenerative diseases
The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration with Denali Therapeutics Inc. to develop...
MD Anderson receives more than $20 million in CPRIT funding
The University of Texas MD Anderson Cancer Center today was awarded more than $20 million from the Cancer Prevention and Research Institute...
Houston Dash join Dynamo, MD Anderson in Making Cancer History
The University of Texas MD Anderson Cancer Center today announced the Houston Dash will join the institution's efforts toward one goal...
Absent p53, oral cancers recruit and reprogram nerves to fuel tumor growth
Loss of an important tumor-suppressing gene allows head and neck cancer to spin off signals to nearby nerves, changing their function and...
CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma
According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric...
Study provides new understanding of mitochondria genome with potential for new avenues of treatment for multiple cancers
A study led by The University of Texas MD Anderson Cancer Center furthered understanding about mitochondria, the cell components known as...
MD Anderson supports World Cancer Day through dedication to eliminate cancer
The University of Texas MD Anderson Cancer Center honors World Cancer Day, Feb. 4, as the campaign celebrates 20 years of bringing awareness...
Craig Owen Named Chief Information Officer
The University of Texas MD Anderson Cancer Center today named Craig Owen as its chief information officer. Owen has served the institution...